Entera Bio Ltd. (NASDAQ:ENTX) Stock Has Consensus Price Target of $9.00 According to Analysts

Shares of Entera Bio Ltd. (NASDAQ:ENTX) have received an average recommendation of “Moderate Buy” from the five ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $9.00.

Several research firms recently issued reports on ENTX. Leerink Partners started coverage on Entera Bio in a research report on Friday, September 18th. They issued an “outperform” rating and a $9.00 target price on the stock. HC Wainwright reiterated a “buy” rating on shares of Entera Bio in a research note on Wednesday, June 24th. Cantor Fitzgerald assumed coverage on Entera Bio in a research note on Tuesday. They set an “overweight” rating on the stock. Guggenheim initiated coverage on Entera Bio in a report on Thursday. They issued a “buy” rating on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Entera Bio in a research note on Friday, July 17th.

Entera Bio Price Performance

Entera Bio stock traded down $0.01 during mid-day trading on Thursday, reaching $2.80. 233,799 shares of the company traded hands, compared to its average volume of 1,036,109. Entera Bio has a fifty-two week low of $0.91 and a fifty-two week high of $4.20. The company has a market capitalization of $486.72 million, a price-to-earnings ratio of -8.00 and a beta of 1.38. The firm’s fifty day moving average is $2.87 and its two-hundred day moving average is $1.85.

Entera Bio (NASDAQ:ENTX) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.06).

Hedge Funds Weigh In On Entera Bio

A hedge fund recently bought a new position in Entera Bio stock. Seven Fleet Capital Management LP acquired a new stake in shares of Entera Bio Ltd. (NASDAQ:ENTX) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 135,318 shares of the company’s stock, valued at approximately $263,000. Seven Fleet Capital Management LP owned 0.30% of Entera Bio at the end of the most recent quarter. 14.11% of the stock is owned by hedge funds and other institutional investors.

About Entera Bio

Entera Bio Ltd. is a biotechnology company developing orally administered therapies based on large-molecule drugs, including proteins and peptides that are traditionally delivered by injection. The company’s proprietary delivery technology is designed to help these molecules pass through the gastrointestinal tract and reach the bloodstream, with the goal of improving convenience and patient adherence.

Entera Bio’s lead programs have focused on bone and mineral disorders. Its pipeline has included EB613, an oral formulation of parathyroid hormone (PTH 1-34, or teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral PTH product candidate intended for hypoparathyroidism.